(CNN)Johnson & Johnson's Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday.
The vaccine was 72% effective against moderate and severe disease in the US, the company said.
The level of protection against moderate and severe COVID-19 infection was 72% in the US, 66% in Latin America and 57% in South Africa, 28 days post-vaccination."
"We're 85% effective at preventing severe disease, which we define as disease that makes you feel particularly sick at home, or may go to the hospital, or worse," Dr. Mathai Mammen, global head of research and development at Johnson & Johnson, told CNN.
"And we are right now completely protective, it would appear 100% protective, against disease that actually does make you go to the hospital, we're 100% protective against death
Dr. Paul Offit, a vaccine expert at the University of Pennsylvania and a member of the FDA's Vaccines and Related Biological Products Advisory Committee, said that under normal circumstances, there might not be much of a market for a vaccine that is significantly less effective than two others already on the market. But he added that these are not normal times, with a pandemic raging and shortage of vaccines.
Mammen said the Janssen vaccine was tested later, after new variants of coronavirus were already circulating. One in particular, called B.1.135, was dominant in South Africa when the vaccine was tested there. This variant has mutations that might be expected to weaken the vaccine's effects somewhat.
But it still protected people, Mammen said.
"I'm looking at that South African variant, and I'm seeing that we're able to completely protect against concerning levels of illness, where one might go to a hospital," he said.
https://amp.cnn.com/cnn/2021/01/29/heal ... rWWDs2QVks
Pa majke mi sad vidim da je cijeli svijet jedna velika disfunkcionalna ublehaška Bosna. 
sve odlicne ideje, ali Bosna 
